Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Assets: 2013-2024

Historic Other Non-Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $26.0 million.

  • Amphastar Pharmaceuticals' Other Non-Current Assets rose 26.21% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 26.21%. This contributed to the annual value of $26.0 million for FY2024, which is 0.32% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Other Non-Current Assets stood at $26.0 million, which was up 0.32% from $25.9 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Non-Current Assets peaked at $26.0 million during FY2024, and registered a low of $5.2 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Other Non-Current Assets had a median value of $25.9 million in 2023 and averaged $24.3 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Other Non-Current Assets crashed by 52.94% in 2020 and then soared by 217.43% in 2021.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Other Non-Current Assets stood at $5.2 million in 2020, then spiked by 217.43% to $16.7 million in 2021, then grew by 25.15% to $20.9 million in 2022, then rose by 24.23% to $25.9 million in 2023, then rose by 0.32% to $26.0 million in 2024.